hims glp 1 compound & Hers swings to a loss in Q1 amid shift in GLP-1 strategy Hims & Hers Selling GLP-1

Uptake in this population remains low and many older patients do not initiate the therapy after an event

They are obesity-focused, not metabolic medicine-focused

Other serious side effects include pancreatitis (pancreatic inflammation), the development of thyroid tumors, and gallbladder problems. Research from 2023 shows that semaglutide, such as Ozempic and Wegovy, and tirzepatide, such as Mounjaro and Zepbound, are more effective than liraglutide for weight loss

Most reported concerns center around perceived results, delivery time, and misunderstandings about how the patch works compared to prescription GLP-1 medications

Logistic regression achieved an auROC of 0.77 (Fig

Certain formulations are FDA-approved to lower the risk of serious cardiovascular events, such as heart attacks and strokes, in adults with heart disease who are overweight or obese